Daily Stock Analysis, CURE, NEURALSTEM INC, priceseries

NEURALSTEM INC. Daily Stock Analysis
Stock Information
Open
54.74
Close
55.42
High
56.06
Low
54.43
Previous Close
54.98
Daily Price Gain
0.44
YTD High
56.06
YTD High Date
Feb 14, 2019
YTD Low
42.44
YTD Low Date
Jan 3, 2019
YTD Price Change
9.79
YTD Gain
21.46%
52 Week High
68.37
52 Week High Date
Oct 1, 2018
52 Week Low
38.59
52 Week Low Date
Apr 2, 2018
52 Week Price Change
6.59
52 Week Gain
13.49%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 31. 2017
29.01
Mar 7. 2017
34.57
24 Trading Days
19.16%
Link
LONG
May 31. 2017
36.31
Jun 29. 2017
41.10
21 Trading Days
13.19%
Link
LONG
Aug 28. 2017
41.07
Sep 19. 2017
45.54
15 Trading Days
10.88%
Link
LONG
Jan 2. 2018
47.95
Jan 30. 2018
57.63
19 Trading Days
20.19%
Link
LONG
Jun 1. 2018
44.82
Jun 18. 2018
47.35
11 Trading Days
5.65%
Link
LONG
Jul 5. 2018
47.38
Jul 20. 2018
50.54
11 Trading Days
6.66%
Link
LONG
Jul 30. 2018
52.62
Sep 4. 2018
59.54
25 Trading Days
13.15%
Link
LONG
Sep 12. 2018
61.00
Oct 4. 2018
65.19
16 Trading Days
6.87%
Link
LONG
Jan 4. 2019
46.45
Jan 28. 2019
49.58
15 Trading Days
6.75%
Link
Company Information
Stock Symbol
CURE
Exchange
NASDAQ
Company URL
http://www.neuralstem.com
Company Phone
301-366-4841
CEO
Richard J. Daly
Headquarters
Maryland
Business Address
20271 GOLDENROD LANE, GERMANTOWN, MD 20876
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001357459
About

Description

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of central nervous system therapies based on its proprietary human neuronal stem cells and stem-cell derived small molecule compounds. The company's stem cell technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its clinical development products include NSI-189, which has completed Phase I clinical trial for the treatment of major depressive disorder, as well as is in Phase I clinical trial for the treatment of other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy; and NSI566 that has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. The company was founded in 1996 and is headquartered in Germantown, Maryland.